Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events, specifically those related to heart failure in patients with type 2 diabetes. Reductions in major adverse cardiovascular event (MACE) outcomes are also observed, but confined largely to patients who have prior cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Shivakumar, Oshini, Sattar, Naveed, Wheeler, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993195/
https://www.ncbi.nlm.nih.gov/pubmed/32003831
http://dx.doi.org/10.1093/ndt/gfz292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993195/
https://www.ncbi.nlm.nih.gov/pubmed/32003831
http://dx.doi.org/10.1093/ndt/gfz292

Ejemplares similares